Global Acquired Immuno Deficiency Syndrome (AIDS) Market- By Drug-Class, Disease Indication, Regions and Forecast (2019-2027)

Global Acquired Immuno Deficiency Syndrome (AIDS) Market size is expected to reach US$ 42.96 Bn. by year 2027 at a CAGR of 5.9% during the forecast period.

Global Acquired Immuno Deficiency Syndrome Market overview:

Acquired Immuno Deficiency Syndrome (AIDS) is a disease caused by HIV which affects the immune system, leaving the body vulnerable to life-threatening infections & cancers. AIDS is the most advanced stage of HIV infection. The Centers for disease control has defined AIDS as beginning when a person with HIV infection has CD4 cell, also called as “T-cell” count below 200. The risk of progression to AIDS decreases by using highly effective antiretroviral therapy (ART) regimens. ART improves the immune system of the patient & substantially increases life expectancy. R&D of various novel drugs that can prove to be a long term cure for HIV and can suppress it throughout the life of an individual. Approval of these new drugs can drive the market during the forecast period. Increasing government initiatives to create awareness regarding HIV/AIDS and its treatment are aiding the growth of this market. However, the stigma attached to HIV/AIDS testing & treatment and the associated adverse effects of some HIV/AIDS drugs are the restraint factors limiting the growth of the market.

Global Acquired Immuno Deficiency Syndrome Market Regional Analysis:

Global Acquired Immuno Deficiency Syndrome (AIDS) Market To know about the Research Methodology :- Request Free Sample Report North America holds the largest market share owing to the presence of key market players and high healthcare expenditure. A large number of R&D initiatives for new drugs are propelling the growth of the market in North America. Following North America, Europe and APAC also hold the largest share in the global market owing to the rising patient pool. APAC countries like India and China are expected to demonstrate comparatively higher CAGR due to the increasing number of patients, during the forecast period.

Scope of Global Acquired Immuno Deficiency Syndrome Market :Inquire before buying

Global Acquired Immuno Deficiency Syndrome Market Segmentation:

Global Acquired Immuno Deficiency Syndrome Market, By Drug-Class:

• Nucleoside Reverse Transcriptase Inhibitors(NRTIs) • Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) • Combination Class Drugs • Entry & fusion inhibitors • Integrase inhibitors

Global Acquired Immuno Deficiency Syndrome Market, By Disease Indication:

• Genetic Disorders • Rare cancers • Rare Blood Disorders • Autoimmune Disorders • Infectious Diseases

Global Acquired Immuno Deficiency Syndrome Market Segment Analysis:

Global Acquired Immuno Deficiency Syndrome (AIDS) Market1 The NRTIs segment holds up to 40% of the market share. NRTIs inhibit reverse transcriptase activity and ultimately arrest viral replication.

Key players operating in Acquired Immuno Deficiency Syndrome (AIDS) Market:

• Shire Plc. • AstraZeneca • Eli Lilly and Company • Merck KGaA • Sanofi • Pfizer • Amgen Inc. • Biogen • Novartis AG • Actelion • Daiichi Sankyo • Boehringer Ingelheim International GmbH • Cipla Inc. • AbbVie Inc. • Bristol-Myers Squibb company • Teva Pharmaceuticals The objective of the report is to present a comprehensive analysis of the Global Acquired Immuno Deficiency Syndrome Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Acquired Immuno Deficiency Syndrome Market dynamics, structure by analyzing the market segments and project the Global Acquired Immuno Deficiency Syndrome Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Acquired Immuno Deficiency Syndrome Market make the report investor’s guide.
Global Acquired Immuno Deficiency Syndrome (AIDS) Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Size, By Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis and Forecast 6.1. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis and Forecast, By Drug-Class 7.1. Introduction and Definition 7.2. Key Findings 7.3. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Drug-Class 7.4. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Size (US$ Mn) Forecast, By Drug-Class 7.5. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis, By Drug-Class 7.6. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Attractiveness Analysis, By Drug-Class 8. Global ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis and Forecast, By Disease Indication 8.1. Introduction and Definition 8.2. Key Findings 8.3. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Disease Indication 8.4. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Size (US$ Mn) Forecast, By Disease Indication 8.5. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis, By Disease Indication 8.6. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Attractiveness Analysis, By Disease Indication 9. Global ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis, By Region 9.1. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Region 9.2. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Size (US$ Mn) Forecast, By Region 9.3. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Attractiveness Analysis, By Region 10. North America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis 10.1. Key Findings 10.2. North America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Overview 10.3. North America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Drug-Class 10.4. North America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 10.4.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 10.4.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 10.4.3. Combination Class Drugs 10.4.4. Entry & fusion inhibitors 10.4.5. Integrase inhibitors 10.5. North America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Disease Indication 10.6. North America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 10.6.1. Genetic Disorders 10.6.2. Rare cancers 10.6.3. Rare Blood Disorders 10.6.4. Autoimmune Disorders 10.6.5. Infectious Diseases 10.7. North America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Country 10.8. North America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Country 10.8.1. U.S. 10.8.2. Canada 10.8.3. Mexico 10.9. North America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis, By Country 10.10. U.S. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 10.10.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 10.10.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 10.10.3. Combination Class Drugs 10.10.4. Entry & fusion inhibitors 10.10.5. Integrase inhibitors 10.11. U.S. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 10.11.1. Genetic Disorders 10.11.2. Rare cancers 10.11.3. Rare Blood Disorders 10.11.4. Autoimmune Disorders 10.11.5. Infectious Diseases 10.12. Canada ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 10.12.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 10.12.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 10.12.3. Combination Class Drugs 10.12.4. Entry & fusion inhibitors 10.12.5. Integrase inhibitors 10.13. Canada ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 10.13.1. Genetic Disorders 10.13.2. Rare cancers 10.13.3. Rare Blood Disorders 10.13.4. Autoimmune Disorders 10.13.5. Infectious Diseases 10.14. Mexico ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 10.14.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 10.14.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 10.14.3. Combination Class Drugs 10.14.4. Entry & fusion inhibitors 10.14.5. Integrase inhibitors 10.15. Mexico ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 10.15.1. Genetic Disorders 10.15.2. Rare cancers 10.15.3. Rare Blood Disorders 10.15.4. Autoimmune Disorders 10.15.5. Infectious Diseases 10.16. North America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Attractiveness Analysis 10.16.1. By Drug-Class 10.16.2. By Disease Indication 10.17. PEST Analysis 10.18. Key Trends 10.19. Key Developments 11. Europe ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis 11.1. Key Findings 11.2. Europe ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Overview 11.3. Europe ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Drug-Class 11.4. Europe ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 11.4.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 11.4.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 11.4.3. Combination Class Drugs 11.4.4. Entry & fusion inhibitors 11.4.5. Integrase inhibitors 11.5. Europe ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Disease Indication 11.6. Europe ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 11.6.1. Genetic Disorders 11.6.2. Rare cancers 11.6.3. Rare Blood Disorders 11.6.4. Autoimmune Disorders 11.6.5. Infectious Diseases 11.7. Europe ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Country 11.8. Europe ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Sweden 11.8.7. CIS countries 11.8.8. Rest of Europe 11.9. Germany ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 11.9.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 11.9.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 11.9.3. Combination Class Drugs 11.9.4. Entry & fusion inhibitors 11.9.5. Integrase inhibitors 11.10. Germany ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 11.10.1. Genetic Disorders 11.10.2. Rare cancers 11.10.3. Rare Blood Disorders 11.10.4. Autoimmune Disorders 11.10.5. Infectious Diseases 11.11. U.K. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 11.11.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 11.11.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 11.11.3. Combination Class Drugs 11.11.4. Entry & fusion inhibitors 11.11.5. Integrase inhibitors 11.12. U.K. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 11.12.1. Genetic Disorders 11.12.2. Rare cancers 11.12.3. Rare Blood Disorders 11.12.4. Autoimmune Disorders 11.12.5. Infectious Diseases 11.13. France ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 11.13.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 11.13.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 11.13.3. Combination Class Drugs 11.13.4. Entry & fusion inhibitors 11.13.5. Integrase inhibitors 11.14. France ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 11.14.1. Genetic Disorders 11.14.2. Rare cancers 11.14.3. Rare Blood Disorders 11.14.4. Autoimmune Disorders 11.14.5. Infectious Diseases 11.15. Italy ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 11.15.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 11.15.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 11.15.3. Combination Class Drugs 11.15.4. Entry & fusion inhibitors 11.15.5. Integrase inhibitors 11.16. Italy ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 11.16.1. Genetic Disorders 11.16.2. Rare cancers 11.16.3. Rare Blood Disorders 11.16.4. Autoimmune Disorders 11.16.5. Infectious Diseases 11.17. Spain ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 11.17.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 11.17.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 11.17.3. Combination Class Drugs 11.17.4. Entry & fusion inhibitors 11.17.5. Integrase inhibitors 11.18. Spain ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 11.18.1. Genetic Disorders 11.18.2. Rare cancers 11.18.3. Rare Blood Disorders 11.18.4. Autoimmune Disorders 11.18.5. Infectious Diseases 11.19. Sweden ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 11.19.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 11.19.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 11.19.3. Combination Class Drugs 11.19.4. Entry & fusion inhibitors 11.19.5. Integrase inhibitors 11.20. Sweden ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 11.20.1. Genetic Disorders 11.20.2. Rare cancers 11.20.3. Rare Blood Disorders 11.20.4. Autoimmune Disorders 11.20.5. Infectious Diseases 11.21. CIS countries ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 11.21.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 11.21.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 11.21.3. Combination Class Drugs 11.21.4. Entry & fusion inhibitors 11.21.5. Integrase inhibitors 11.22. CIS countries ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 11.22.1. Genetic Disorders 11.22.2. Rare cancers 11.22.3. Rare Blood Disorders 11.22.4. Autoimmune Disorders 11.22.5. Infectious Diseases 11.23. Rest of Europe ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 11.23.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 11.23.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 11.23.3. Combination Class Drugs 11.23.4. Entry & fusion inhibitors 11.23.5. Integrase inhibitors 11.24. Rest of Europe ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 11.24.1. Genetic Disorders 11.24.2. Rare cancers 11.24.3. Rare Blood Disorders 11.24.4. Autoimmune Disorders 11.24.5. Infectious Diseases 11.25. Europe ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Attractiveness Analysis 11.25.1. By Disease Indication 11.25.2. By Drug-Class 11.26. PEST Analysis 11.27. Key Trends 11.28. Key Developments 12. Asia Pacific ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis 12.1. Key Findings 12.2. Asia Pacific ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Overview 12.3. Asia Pacific ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Drug-Class 12.4. Asia Pacific ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 12.4.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 12.4.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 12.4.3. Combination Class Drugs 12.4.4. Entry & fusion inhibitors 12.4.5. Integrase inhibitors 12.5. Asia Pacific ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Disease Indication 12.6. Asia Pacific ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 12.6.1. Genetic Disorders 12.6.2. Rare cancers 12.6.3. Rare Blood Disorders 12.6.4. Autoimmune Disorders 12.6.5. Infectious Diseases 12.7. Asia Pacific ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Country 12.8. Asia Pacific ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. South Korea 12.8.5. Australia 12.8.6. ASEAN 12.8.7. Rest of Asia Pacific 12.9. Asia Pacific ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis, By Country 12.10. China ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 12.10.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 12.10.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 12.10.3. Combination Class Drugs 12.10.4. Entry & fusion inhibitors 12.10.5. Integrase inhibitors 12.11. China ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 12.11.1. Genetic Disorders 12.11.2. Rare cancers 12.11.3. Rare Blood Disorders 12.11.4. Autoimmune Disorders 12.11.5. Infectious Diseases 12.12. India ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 12.12.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 12.12.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 12.12.3. Combination Class Drugs 12.12.4. Entry & fusion inhibitors 12.12.5. Integrase inhibitors 12.13. India ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 12.13.1. Genetic Disorders 12.13.2. Rare cancers 12.13.3. Rare Blood Disorders 12.13.4. Autoimmune Disorders 12.13.5. Infectious Diseases 12.14. Japan ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 12.14.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 12.14.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 12.14.3. Combination Class Drugs 12.14.4. Entry & fusion inhibitors 12.14.5. Integrase inhibitors 12.15. Japan ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 12.15.1. Genetic Disorders 12.15.2. Rare cancers 12.15.3. Rare Blood Disorders 12.15.4. Autoimmune Disorders 12.15.5. Infectious Diseases 12.16. South Korea ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 12.16.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 12.16.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 12.16.3. Combination Class Drugs 12.16.4. Entry & fusion inhibitors 12.16.5. Integrase inhibitors 12.17. South Korea ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 12.17.1. Genetic Disorders 12.17.2. Rare cancers 12.17.3. Rare Blood Disorders 12.17.4. Autoimmune Disorders 12.17.5. Infectious Diseases 12.18. Australia ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 12.18.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 12.18.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 12.18.3. Combination Class Drugs 12.18.4. Entry & fusion inhibitors 12.18.5. Integrase inhibitors 12.19. Australia ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 12.19.1. Genetic Disorders 12.19.2. Rare cancers 12.19.3. Rare Blood Disorders 12.19.4. Autoimmune Disorders 12.19.5. Infectious Diseases 12.20. ASEAN ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 12.20.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 12.20.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 12.20.3. Combination Class Drugs 12.20.4. Entry & fusion inhibitors 12.20.5. Integrase inhibitors 12.21. ASEAN ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 12.21.1. Genetic Disorders 12.21.2. Rare cancers 12.21.3. Rare Blood Disorders 12.21.4. Autoimmune Disorders 12.21.5. Infectious Diseases 12.22. Rest of Asia Pacific ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 12.22.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 12.22.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 12.22.3. Combination Class Drugs 12.22.4. Entry & fusion inhibitors 12.22.5. Integrase inhibitors 12.23. Rest of Asia Pacific ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 12.23.1. Genetic Disorders 12.23.2. Rare cancers 12.23.3. Rare Blood Disorders 12.23.4. Autoimmune Disorders 12.23.5. Infectious Diseases 12.24. Asia Pacific ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Attractiveness Analysis 12.24.1. By Drug-Class 12.24.2. By Disease Indication 12.25. PEST Analysis 12.26. Key Trends 12.27. Key Developments 13. Middle East & Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis 13.1. Key Findings 13.2. Middle East & Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Overview 13.3. Middle East & Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Drug-Class 13.4. Middle East & Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 13.4.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 13.4.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 13.4.3. Combination Class Drugs 13.4.4. Entry & fusion inhibitors 13.4.5. Integrase inhibitors 13.5. Middle East & Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Disease Indication 13.6. Middle East & Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 13.6.1. Genetic Disorders 13.6.2. Rare cancers 13.6.3. Rare Blood Disorders 13.6.4. Autoimmune Disorders 13.6.5. Infectious Diseases 13.7. Middle East & Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Country 13.8. Middle East & Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Country 13.8.1. GCC Countries 13.8.2. South Africa 13.8.3. Nigeria 13.8.4. Egypt 13.8.5. Rest of Middle East & Africa 13.9. Middle East & Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis, By Country 13.10. GCC Countries ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 13.10.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 13.10.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 13.10.3. Combination Class Drugs 13.10.4. Entry & fusion inhibitors 13.10.5. Integrase inhibitors 13.11. GCC Countries ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 13.11.1. Genetic Disorders 13.11.2. Rare cancers 13.11.3. Rare Blood Disorders 13.11.4. Autoimmune Disorders 13.11.5. Infectious Diseases 13.12. South Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 13.12.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 13.12.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 13.12.3. Combination Class Drugs 13.12.4. Entry & fusion inhibitors 13.12.5. Integrase inhibitors 13.13. South Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 13.13.1. Genetic Disorders 13.13.2. Rare cancers 13.13.3. Rare Blood Disorders 13.13.4. Autoimmune Disorders 13.13.5. Infectious Diseases 13.14. Nigeria ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 13.14.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 13.14.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 13.14.3. Combination Class Drugs 13.14.4. Entry & fusion inhibitors 13.14.5. Integrase inhibitors 13.15. Nigeria ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 13.15.1. Genetic Disorders 13.15.2. Rare cancers 13.15.3. Rare Blood Disorders 13.15.4. Autoimmune Disorders 13.15.5. Infectious Diseases 13.16. Egypt ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 13.16.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 13.16.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 13.16.3. Combination Class Drugs 13.16.4. Entry & fusion inhibitors 13.16.5. Integrase inhibitors 13.17. Egypt ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 13.17.1. Genetic Disorders 13.17.2. Rare cancers 13.17.3. Rare Blood Disorders 13.17.4. Autoimmune Disorders 13.17.5. Infectious Diseases 13.18. Rest of Middle East & Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 13.18.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 13.18.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 13.18.3. Combination Class Drugs 13.18.4. Entry & fusion inhibitors 13.18.5. Integrase inhibitors 13.19. Rest of Middle East & Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 13.19.1. Genetic Disorders 13.19.2. Rare cancers 13.19.3. Rare Blood Disorders 13.19.4. Autoimmune Disorders 13.19.5. Infectious Diseases 13.20. Middle East & Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Attractiveness Analysis 13.20.1. By Drug-Class 13.20.2. By Disease Indication 13.21. PEST Analysis 13.22. Key Trends 13.23. Key Developments 14. South America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis 14.1. Key Findings 14.2. South America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Overview 14.3. South America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Drug-Class 14.4. South America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 14.4.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 14.4.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 14.4.3. Combination Class Drugs 14.4.4. Entry & fusion inhibitors 14.4.5. Integrase inhibitors 14.5. South America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Disease Indication 14.6. South America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 14.6.1. Genetic Disorders 14.6.2. Rare cancers 14.6.3. Rare Blood Disorders 14.6.4. Autoimmune Disorders 14.6.5. Infectious Diseases 14.7. South America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Country 14.8. South America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Country 14.8.1. Brazil 14.8.2. Colombia 14.8.3. Argentina 14.8.4. Rest of South America 14.9. South America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis, By Country 14.10. Brazil ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 14.10.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 14.10.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 14.10.3. Combination Class Drugs 14.10.4. Entry & fusion inhibitors 14.10.5. Integrase inhibitors 14.11. Brazil ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 14.11.1. Genetic Disorders 14.11.2. Rare cancers 14.11.3. Rare Blood Disorders 14.11.4. Autoimmune Disorders 14.11.5. Infectious Diseases 14.12. Colombia ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 14.12.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 14.12.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 14.12.3. Combination Class Drugs 14.12.4. Entry & fusion inhibitors 14.12.5. Integrase inhibitors 14.13. Colombia ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 14.13.1. Genetic Disorders 14.13.2. Rare cancers 14.13.3. Rare Blood Disorders 14.13.4. Autoimmune Disorders 14.13.5. Infectious Diseases 14.14. Argentina ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 14.14.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 14.14.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 14.14.3. Combination Class Drugs 14.14.4. Entry & fusion inhibitors 14.14.5. Integrase inhibitors 14.15. Argentina ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 14.15.1. Genetic Disorders 14.15.2. Rare cancers 14.15.3. Rare Blood Disorders 14.15.4. Autoimmune Disorders 14.15.5. Infectious Diseases 14.16. Rest of South America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class 14.16.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs) 14.16.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 14.16.3. Combination Class Drugs 14.16.4. Entry & fusion inhibitors 14.16.5. Integrase inhibitors 14.17. Rest of South America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication 14.17.1. Genetic Disorders 14.17.2. Rare cancers 14.17.3. Rare Blood Disorders 14.17.4. Autoimmune Disorders 14.17.5. Infectious Diseases 14.18. South America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Attractiveness Analysis 14.18.1. By Drug-Class 14.18.2. By Disease Indication 14.19. PEST Analysis 14.20. Key Trends 14.21. Key Developments 15. Company Profiles 15.1. Market Share Analysis, By Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players By price, presence, market share, Component, and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A By Regions, Investment and Component 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Shire Plc. 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Development Footprint 15.3.2. AstraZeneca 15.3.3. Eli Lilly and Company 15.3.4. Merck KGaA 15.3.5. Sanofi 15.3.6. Pfizer 15.3.7. Amgen Inc. 15.3.8. Biogen 15.3.9. Novartis AG 15.3.10. Actelion 15.3.11. Daiichi Sankyo 15.3.12. Boehringer Ingelheim International GmbH 15.3.13. Cipla Inc. 15.3.14. AbbVie Inc. 15.3.15. Bristol-Myers Squibb company 15.3.16. Teva Pharmaceuticals 16. Primary key Insights

About This Report

Report ID 81740
Category Healthcare
Published Date February 2021
Updated Date Oct 2021
Contact Us